ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer.


Journal

BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628

Informations de publication

Date de publication:
14 05 2020
Historique:
received: 15 08 2019
accepted: 30 04 2020
entrez: 16 5 2020
pubmed: 16 5 2020
medline: 11 5 2021
Statut: epublish

Résumé

Chromothripsis is an event of genomic instability leading to complex chromosomal alterations in cancer. Frequent long-range chromatin interactions between transcription factors (TFs) and targets may promote extensive translocations and copy-number alterations in proximal contact regions through inappropriate DNA stitching. Although studies have proposed models to explain the initiation of chromothripsis, few discussed how TFs influence this process for tumor progression. This study focused on genomic alterations in amplification associated regions within chromosome 17. Inter-/intra-chromosomal rearrangements were analyzed using whole genome sequencing data of breast tumors in the Cancer Genome Atlas (TCGA) cohort. Common ERα binding sites were defined based on MCF-7, T47D, and MDA-MB-134 breast cancer cell lines using univariate K-means clustering methods. Nanopore sequencing technology was applied to validate frequent rearrangements detected between ATC loci on 17q23 and an ERα hub on 20q13. The efficacy of pharmacological inhibition of a potentially druggable target gene on 17q23 was evaluated using breast cancer cell lines and patient-derived circulating breast tumor cells. There are five adjoining regions from 17q11.1 to 17q24.1 being hotspots of chromothripsis. Inter-/intra-chromosomal rearrangements of these regions occurred more frequently in ERα-positive tumors than in ERα-negative tumors. In addition, the locations of the rearrangements were often mapped within or close to dense ERα binding sites localized on these five 17q regions or other chromosomes. This chromothriptic event was linked to concordant upregulation of 96 loci that predominantly regulate cell-cycle machineries in advanced luminal tumors. Genome-editing analysis confirmed that an ERα hub localized on 20q13 coordinately regulates a subset of these loci localized on 17q23 through long-range chromosome interactions. One of these loci, Tousled Like Kinase 2 (TLK2) known to participate in DNA damage checkpoint control, is an actionable target using phenothiazine antipsychotics (PTZs). The antiproliferative effect of PTZs was prominent in high TLK2-expressing cells, compared to low expressing cells. This study demonstrates a new approach for identifying tumorigenic drivers from genomic regions highly susceptible to ERα-related chromothripsis. We found a group of luminal breast tumors displaying 17q-related chromothripsis for which antipsychotics can be repurposed as treatment adjuncts.

Sections du résumé

BACKGROUND
Chromothripsis is an event of genomic instability leading to complex chromosomal alterations in cancer. Frequent long-range chromatin interactions between transcription factors (TFs) and targets may promote extensive translocations and copy-number alterations in proximal contact regions through inappropriate DNA stitching. Although studies have proposed models to explain the initiation of chromothripsis, few discussed how TFs influence this process for tumor progression.
METHODS
This study focused on genomic alterations in amplification associated regions within chromosome 17. Inter-/intra-chromosomal rearrangements were analyzed using whole genome sequencing data of breast tumors in the Cancer Genome Atlas (TCGA) cohort. Common ERα binding sites were defined based on MCF-7, T47D, and MDA-MB-134 breast cancer cell lines using univariate K-means clustering methods. Nanopore sequencing technology was applied to validate frequent rearrangements detected between ATC loci on 17q23 and an ERα hub on 20q13. The efficacy of pharmacological inhibition of a potentially druggable target gene on 17q23 was evaluated using breast cancer cell lines and patient-derived circulating breast tumor cells.
RESULTS
There are five adjoining regions from 17q11.1 to 17q24.1 being hotspots of chromothripsis. Inter-/intra-chromosomal rearrangements of these regions occurred more frequently in ERα-positive tumors than in ERα-negative tumors. In addition, the locations of the rearrangements were often mapped within or close to dense ERα binding sites localized on these five 17q regions or other chromosomes. This chromothriptic event was linked to concordant upregulation of 96 loci that predominantly regulate cell-cycle machineries in advanced luminal tumors. Genome-editing analysis confirmed that an ERα hub localized on 20q13 coordinately regulates a subset of these loci localized on 17q23 through long-range chromosome interactions. One of these loci, Tousled Like Kinase 2 (TLK2) known to participate in DNA damage checkpoint control, is an actionable target using phenothiazine antipsychotics (PTZs). The antiproliferative effect of PTZs was prominent in high TLK2-expressing cells, compared to low expressing cells.
CONCLUSION
This study demonstrates a new approach for identifying tumorigenic drivers from genomic regions highly susceptible to ERα-related chromothripsis. We found a group of luminal breast tumors displaying 17q-related chromothripsis for which antipsychotics can be repurposed as treatment adjuncts.

Identifiants

pubmed: 32408897
doi: 10.1186/s12920-020-0729-7
pii: 10.1186/s12920-020-0729-7
pmc: PMC7222439
doi:

Substances chimiques

Biomarkers, Tumor 0
ESR1 protein, human 0
Estrogen Receptor alpha 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

69

Subventions

Organisme : NCI NIH HHS
ID : U54 CA113001
Pays : United States
Organisme : Cancer Prevention and Research Institute of Texas (US)
ID : RP170345
Pays : International
Organisme : NCI NIH HHS
ID : P30 CA054174
Pays : United States
Organisme : Cancer Prevention and Research Institute of Texas
ID : RP150600
Pays : International
Organisme : NCI NIH HHS
ID : U54 CA217297
Pays : United States

Références

R J. 2011 Dec;3(2):29-33
pubmed: 27942416
Cancer Res. 2016 Oct 1;76(19):5634-5646
pubmed: 27457520
J Clin Oncol. 2009 Apr 1;27(10):1627-36
pubmed: 19255330
Cold Spring Harb Perspect Biol. 2010 Oct;2(10):a003236
pubmed: 20719876
Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1227-31
pubmed: 22941581
Cancer Cell. 2013 Aug 12;24(2):197-212
pubmed: 23948299
Lancet. 2016 Jan 2;387(10013):70-82
pubmed: 26074382
Genomics. 2007 May;89(5):580-7
pubmed: 17369017
Nature. 2017 Jan 19;541(7637):359-364
pubmed: 28068672
PLoS One. 2013 Apr 22;8(4):e60980
pubmed: 23630576
Nat Methods. 2009 Sep;6(9):677-81
pubmed: 19668202
Oncogene. 2016 May 5;35(18):2379-89
pubmed: 26300005
Trends Mol Med. 2019 Jul;25(7):595-611
pubmed: 31078431
Carcinogenesis. 2013 Sep;34(9):2080-9
pubmed: 23689352
Oncol Rep. 2006 Jan;15(1):107-12
pubmed: 16328041
Aust N Z J Psychiatry. 2017 Dec;51(12):1256
pubmed: 28891312
Sci Rep. 2016 Jun 09;6:27540
pubmed: 27277973
Nature. 2011 Feb 10;470(7333):227-32
pubmed: 21307936
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11651-6
pubmed: 16087863
Nat Rev Cancer. 2012 Oct;12(10):663-70
pubmed: 22972457
Oncogene. 2018 May;37(19):2586-2600
pubmed: 29467493
Life Sci Alliance. 2018 Jun 7;1(3):e201800055
pubmed: 30456355
Clin Cancer Res. 2007 Aug 15;13(16):4909-19
pubmed: 17699871
Leukemia. 2017 Oct;31(10):2048-2056
pubmed: 28196983
Genome Res. 2011 Mar;21(3):487-93
pubmed: 21209072
Front Oncol. 2014 May 01;4:80
pubmed: 24822169
Nat Commun. 2018 Jun 28;9(1):2535
pubmed: 29955062
Oncogene. 2015 Aug 13;34(33):4379-90
pubmed: 25381815
Cell. 2012 Jun 8;149(6):1284-97
pubmed: 22632761
Cancer Res. 2008 Mar 1;68(5):1471-7
pubmed: 18316611
Cancer Chemother Pharmacol. 2004 Mar;53(3):267-75
pubmed: 14663628
Genes Chromosomes Cancer. 1998 Oct;23(2):141-52
pubmed: 9739017
Genome Res. 2009 Sep;19(9):1639-45
pubmed: 19541911
Nat Genet. 2020 Mar;52(3):331-341
pubmed: 32025003
Genome Biol. 2018 Oct 4;19(1):151
pubmed: 30286773
Nat Commun. 2016 Oct 03;7:12991
pubmed: 27694828
Int J Cancer. 1997 Feb 20;74(1):86-93
pubmed: 9036875
Genes Dev. 2014 Oct 1;28(19):2151-62
pubmed: 25274727
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7012-22
pubmed: 16203795
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Nat Protoc. 2016 Feb;11(2):347-58
pubmed: 26797458
PLoS One. 2011;6(11):e27186
pubmed: 22087264
J Clin Oncol. 2010 Apr 1;28(10):1684-91
pubmed: 20194857
Clin Epigenetics. 2015 Feb 24;7:13
pubmed: 25763113
Genes Chromosomes Cancer. 2002 Dec;35(4):353-8
pubmed: 12378529
Genes Chromosomes Cancer. 1997 Jan;18(1):59-65
pubmed: 8993981
Nat Genet. 2009 May;41(5):585-90
pubmed: 19330027
Nat Rev Genet. 2018 Dec;19(12):789-800
pubmed: 30367165
Breast Cancer Res. 2011 Feb 02;13(1):R15
pubmed: 21288332
Cancer Res. 2002 Apr 15;62(8):2359-64
pubmed: 11956097
Nucleic Acids Res. 2019 Jan 8;47(D1):D729-D735
pubmed: 30462313
J Clin Invest. 2014 Feb;124(2):644-55
pubmed: 24401270
BMC Cancer. 2010 Oct 08;10:539
pubmed: 20932292
Bone. 2017 Sep;102:69-79
pubmed: 27760307
Genes Dev. 2013 Dec 1;27(23):2513-30
pubmed: 24298051
Am J Pathol. 1999 Jan;154(1):37-43
pubmed: 9916916
Nature. 2012 Apr 11;485(7398):376-80
pubmed: 22495300
EMBO Rep. 2016 May;17(5):659-70
pubmed: 26931568
BMC Genomics. 2014 Jul 09;15:579
pubmed: 25011954
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Curr Biol. 2015 Oct 19;25(20):R1002-18
pubmed: 26485365
Nat Genet. 2012 Mar 04;44(4):390-7, S1
pubmed: 22388000
PLoS Biol. 2006 May;4(5):e138
pubmed: 16623600
Nature. 2015 Oct 29;526(7575):700-4
pubmed: 26466568
Exp Mol Med. 2010 May 31;42(5):395-405
pubmed: 20368687
Cell Death Dis. 2011 Jul 21;2:e181
pubmed: 21776019
Nat Neurosci. 2016 Mar;19(3):517-22
pubmed: 26829649
Carcinogenesis. 2014 Mar;35(3):670-82
pubmed: 24148822
Sci Rep. 2016 Oct 13;6:34651
pubmed: 27734896
Genes Cancer. 2013 Jan;4(1-2):39-53
pubmed: 23946870
Am J Pathol. 2010 May;176(5):2113-30
pubmed: 20348243
Science. 2019 May 3;364(6439):
pubmed: 31048460
Cancer Res. 1994 Apr 1;54(7):1801-6
pubmed: 8137295
Cancer Cell. 2014 Nov 10;26(5):653-67
pubmed: 25517748
J Cell Biol. 2010 Jul 26;190(2):197-207
pubmed: 20660628
Clin Cancer Res. 2010 Jan 15;16(2):376-83
pubmed: 20068082

Auteurs

Chun-Lin Lin (CL)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.

Xi Tan (X)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.

Meizhen Chen (M)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.

Meena Kusi (M)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.

Chia-Nung Hung (CN)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.

Chih-Wei Chou (CW)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.

Ya-Ting Hsu (YT)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.

Chiou-Miin Wang (CM)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.

Nameer Kirma (N)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.

Chun-Liang Chen (CL)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.

Ching-Hung Lin (CH)

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Kate I Lathrop (KI)

Department of Medicine, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Richard Elledge (R)

Department of Medicine, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Virginia G Kaklamani (VG)

Department of Medicine, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Kohzoh Mitsuya (K)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA. mitsuya@uthscsa.edu.

Tim H-M Huang (TH)

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA. huangt3@uthscsa.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH